GOTHENBURG, Sweden and London, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Albireo Limited, a clinical-stage biopharmaceutical company developing through its operating subsidiary novel bile acid modulators to treat rare pediatric liver diseases, NASH, and gastrointestinal disorders, announced today that Albireo scientists will present a poster of clinical data for A4250 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held from November 13 through November 17 in San Francisco, California. A4250, Albireo's lead product candidate, is being developed as a treatment for rare pediatric liver diseases and nonalcoholic steatohepatitis (NASH).
Albireo's poster, titled "The Ileal Bile Acid Transporter Inhibitor A4250 Modulates Bile Acid Synthesis and Decreases Serum Bile Acids," is scheduled to be presented on Sunday, November 15, 2015. The poster includes data from a double-blind Phase 1 single and multiple ascending dose clinical trial designed to assess the safety, pharmacokinetics and pharmacodynamics of A4250 in healthy volunteers.
"Our data to be presented at the AASLD meeting highlight the promise of A4250 in reducing serum bile acids, which are typically elevated in cholestatic liver disease and often associated with severe liver damage, as well as the compound's minimal systemic exposure at therapeutically relevant doses and favorable safety and tolerability profile," said Ron Cooper, Albireo's President and Chief Executive Officer. "Enrollment continues in two ongoing Phase 2 clinical trials of A4250, one in pediatric cholestatic pruritus and one in primary biliary cirrhosis."
A4250 is a first-in-class product candidate in development for rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), and nonalcoholic steatohepatitis (NASH). A4250 is a highly potent and selective inhibitor of the ileal bile acid transporter that acts locally in the gut, has minimal systemic exposure and is excreted substantially intact, resulting in a reduced risk of systemic side effects and undesirable drug-drug interactions. A4250, which is currently being evaluated in Phase 2 clinical trials in pediatric cholestatic pruritus and primary biliary cirrhosis, has been granted orphan drug designation in the United States and the European Union for PFIC, as well as certain other cholestatic liver diseases.
Albireo Limited is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel locally acting bile acid modulators to treat diseases in which there is high unmet medical need, including rare pediatric liver diseases, nonalcoholic steatohepatitis (NASH), and debilitating gastrointestinal disorders. Albireo's clinical pipeline includes two Phase 2 product candidates and one Phase 3 product candidate. Albireo was spun out from AstraZeneca in 2008 and is backed by top-tier life science investors such as Phase IV Ventures, TPG Biotech, TVM Capital Life Science and Aberdeen Asset Management, as well as AstraZeneca.
Albireo Limited is incorporated and registered in England and Wales, and its wholly owned subsidiaries are located in Gothenburg, Sweden (including its operating subsidiary Albireo AB) and Boston, Massachusetts. For more information on Albireo, please visit www.albireopharma.com.
Albireo is a registered trademark of Albireo AB in key pharmaceutical markets in Europe.
CONTACT: Albireo Contact: Jan Mattsson Chief Operating Officer Tel: +46 31 741 14 80 email@example.com